- Home
- PRZO vs CERO Comparison
PRZO vs CERO Comparison
Compare PRZO & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRZO
- CERO
- Stock Information
- Founded
- PRZO 2014
- CERO 2017
- Country
- PRZO Israel
- CERO United States
- Employees
- PRZO N/A
- CERO N/A
- Industry
- PRZO
- CERO
- Sector
- PRZO
- CERO
- Exchange
- PRZO Nasdaq
- CERO Nasdaq
- Market Cap
- PRZO 20.1M
- CERO 3.5M
- IPO Year
- PRZO 2023
- CERO N/A
- Fundamental
- Price
- PRZO $1.35
- CERO $9.40
- Analyst Decision
- PRZO
- CERO Strong Buy
- Analyst Count
- PRZO 0
- CERO 2
- Target Price
- PRZO N/A
- CERO $45.00
- AVG Volume (30 Days)
- PRZO 1.7M
- CERO 3.3M
- Earning Date
- PRZO 03-21-2025
- CERO 08-13-2025
- Dividend Yield
- PRZO N/A
- CERO N/A
- EPS Growth
- PRZO N/A
- CERO N/A
- EPS
- PRZO N/A
- CERO N/A
- Revenue
- PRZO $932,154.00
- CERO N/A
- Revenue This Year
- PRZO N/A
- CERO N/A
- Revenue Next Year
- PRZO N/A
- CERO N/A
- P/E Ratio
- PRZO N/A
- CERO N/A
- Revenue Growth
- PRZO 50.22
- CERO N/A
- 52 Week Low
- PRZO $0.49
- CERO $6.71
- 52 Week High
- PRZO $3.16
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- PRZO 61.79
- CERO 47.17
- Support Level
- PRZO $1.12
- CERO $9.10
- Resistance Level
- PRZO $1.30
- CERO $9.73
- Average True Range (ATR)
- PRZO 0.10
- CERO 2.73
- MACD
- PRZO 0.00
- CERO 0.08
- Stochastic Oscillator
- PRZO 78.79
- CERO 12.57
About PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.